Phase II study of a BD-HDM regimen for multiple myeloma patients

Phase II study of a BD-HDM regimen for multiple myeloma patients - BD-HDM trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005674

Enrollment

Registered

2011-05-30

Start date

2010-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

multiple myeloma

Interventions

BD-HDM

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: According to the International Myeloma Working Group (IMWG) criteria20, patients younger than 65 years with symptomatic MM were eligible for this trial.

Exclusion criteria

Exclusion criteria: The exclusion criteria were a serum creatinine level&#61619;2.05 mg/dL at time of high-dose therapy (HDT), liver dysfunction (e.g., a serum total bilirubin level&#61619;2.0 mg/dL, or serum aspartate/alanine aminotransferase or alkaline phosphatase levels more than 2.5 times the upper limit of normal), grade 3 or worse peripheral neuropathy, significant comorbidity that would preclude ASCT, poor performance status (&#61619;grade 3), and a history of any other malignancy with the exception of basal cell carcinoma and stage I cervical cancer.

Design outcomes

Primary

Measure	Time frame
toxicity	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026